August 6 marks a significant milestone for NanoEcho! We are now listed on Nasdaq First North Growth Market. We are incredibly proud of the hard work that has made this possible. A big thank you to all the investors who have continued to trust us, and a warm welcome to all new investors to NanoEcho!
Here are some highlights from today’s ceremony and the live broadcast of the bell ringing:
NanoEcho’s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.
Not For Sale – For Clinical Investigation Use Only – EU Trial No.: 2024-515335-29-00